A specific lot of the widely prescribed anti-anxiety medication Xanax XR has been recalled nationwide due to quality control concerns, according to an announcement from the U.S. Food and Drug Administration (FDA). The recall, initiated by Viatris Specialty LLC, a distributor based in West Virginia, affects 3-milligram extended-release tablets of Xanax XR packaged in bottles of 60. The action follows failed dissolution tests, which assess how quickly the medication releases its active ingredient after ingestion.
The FDA classified the recall as Class II, indicating that employ of the affected product may cause temporary or medically reversible adverse health consequences, or that the probability of serious harm is remote. Patients who have been prescribed this formulation of Xanax XR are advised to check their medication bottles immediately and discontinue use if they match the recalled lot details. The agency emphasized that while the defect does not appear to pose an immediate life-threatening risk, consistent dosing is critical for medications treating conditions like panic disorder.
The recalled lot carries the number 8177156 and has an expiration date of February 28, 2027. According to the California State Board of Pharmacy, which issued a complementary notice, the batch was distributed between August 27, 2024, and May 29, 2025. These dates represent the window during which the affected tablets may have reached pharmacies, healthcare providers, and patients across the United States. The dissolution failure specifically relates to the time it takes for the pill to break down in the gastrointestinal tract, a factor that can influence both the onset and duration of the drug’s therapeutic effect.
Xanax XR, the extended-release formulation of alprazolam, is commonly prescribed for the treatment of panic disorder with or without agoraphobia in adults. Unlike immediate-release versions, Xanax XR is designed to release the active ingredient slowly over time, maintaining steady blood levels throughout the day. When a drug fails dissolution testing, as in this case, there is a risk that the medication may not dissolve at the intended rate, potentially leading to inconsistent absorption and reduced effectiveness—or, conversely, unexpected spikes in concentration if the tablet breaks down too quickly in certain individuals.
The FDA’s notice, posted on April 15, 2026, directed patients to return the recalled product to their pharmacy or place of purchase for a refund or replacement. Viatris Specialty LLC confirmed the voluntary nature of the recall and stated that it was working closely with regulatory authorities to ensure the affected lots were removed from circulation. The company did not disclose the total number of bottles involved in the recall but affirmed that no other lots of Xanax XR or other strengths of the medication are impacted by this action.
For patients currently taking Xanax XR, medical professionals recommend against abruptly stopping the medication without consulting a healthcare provider, even if their batch is recalled. Sudden discontinuation of benzodiazepines like alprazolam can lead to withdrawal symptoms, including increased anxiety, insomnia, irritability, and in rare cases, seizures. Instead, individuals should contact their prescribing physician or pharmacist to verify whether their medication is part of the recalled lot and to discuss appropriate next steps, which may include obtaining a replacement from an unaffected batch.
This recall adds to a series of recent quality-related actions involving psychiatric medications, underscoring ongoing scrutiny of manufacturing and testing processes in the pharmaceutical supply chain. While isolated, such events highlight the importance of post-market surveillance systems operated by agencies like the FDA, which rely on dissolution testing and other quality control measures to detect deviations before they reach widespread patient use. The agency continues to monitor the situation and has encouraged healthcare professionals and consumers to report any adverse events or concerns related to the recalled product through its MedWatch program.
As of the date of this report, no additional lots or formulations of Xanax have been recalled in connection with this incident. The FDA maintains an updated list of active recalls on its official website, where patients and providers can search by lot number, product name, or date to verify the status of their medication. Individuals seeking further information are advised to consult the FDA’s recall notice dated April 15, 2026, or contact Viatris Specialty LLC directly for assistance with returns or replacements.
Stay informed about medication safety updates by following trusted sources such as the U.S. Food and Drug Administration and speaking openly with your healthcare team about any concerns regarding your prescriptions. If you have experience with this recall or questions about managing your anxiety treatment safely, we invite you to share your thoughts in the comments below or share this article to help others stay informed.
Related reading